Israel's greatest asset is its people with their novel ideas. Whereas Hi Tech in Israel has moved from strength to strengh, Israeli biotech remains neglected due to lack of substantial funding by Big Pharma. Teva became a giant due to its sales of a novel Weizmann blockbuster drug (Copaxone) but today invests more than 90% of its efforts in aquisitions/development of novel generic drugs. It would be a welcome change if Teva changes their strategy to put equal investment into new drugs developed from the Israeli scientific community.
Hello user Logout | profile
You have watched of 10 articles
French Foreign Minister Fabius says he will leave office (Reuters)